Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial

被引：0
|
作者：
Ferreira, J. P. [1 ]
Verma, S. [2 ]
David, F. [3 ]
Ofstad, A. P. [4 ]
Lauer, S. [5 ]
Zwiener, I. [5 ]
George, J. T. [6 ]
Wanner, C. [7 ]
Zinman, B. [8 ]
Inzucchi, S. E. [9 ]
机构：
[1] Univ Lorraine, Inserm 1433, Ctr Invest Clin Plurithemat, Nancy, France
[2] Univ Toronto, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Boehringer Ingelheim Norway KS, Asker, Norway
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Wurzburg Univ Clin, Wurzburg, Germany
[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[9] Yale Univ, Sch Med, New Haven, CT USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
947
引用
收藏
页码：S450 / S451
页数：2
相关论文
共 50 条
  • [21] Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffrey
    Ofstad, Anne-Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina J.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S103 - S103
  • [22] Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
    Pellicori, Pierpaolo
    Fitchett, David
    Kosiborod, Mikhail N.
    Ofstad, Anne P.
    Seman, Leo
    Zinman, Bernard
    Zwiener, Isabella
    Wanner, Christoph
    George, Jyothis
    Inzucchi, Silvio E.
    Testani, Jeffrey M.
    Cleland, John G. F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) : 1085 - 1093
  • [23] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [24] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    George, Jyothis T.
    Johansen, Odd Erik
    Fitchett, David
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
  • [25] EMPA-REG OUTCOME: A Milestone in the Treatment of the Diabetes mellitus Type 2?
    Schneider, C. A.
    Pfuetzner, A.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 405 - 407
  • [26] Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
    Ryden, Lars
    Shahim, Bahira
    Mellbin, Linda
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1279 - 1287
  • [27] Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial
    Kansal, A.
    Reifsnider, O. S.
    Proskorovsky, I.
    Zheng, Y.
    Pfarr, E.
    George, J. T.
    Kandaswamy, P.
    Ruffolo, A.
    DIABETIC MEDICINE, 2019, 36 (11) : 1494 - 1502
  • [28] Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
    Ferreira, Joao Pedro
    Kraus, Bettina Johanna
    Zwiener, Isabella
    Lauer, Sabine
    Zinman, Bernard
    Fitchett, David H.
    Koitka-Weber, Audrey
    George, Jyothis T.
    Ofstad, Anne Pernille
    Wanner, Christoph
    Zannad, Faiez
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [29] Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
    Verma, Subodh
    Mazer, C. David
    Al-Omran, Mohammed
    Inzucchi, Silvio E.
    Fitchett, David
    Hehnke, Uwe
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 137 (04) : 405 - 407
  • [30] THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME
    Verma, Subodh
    Mazer, C. David
    Inzucchi, Silvio E.
    Wanner, Christoph
    Ofstad, Anne Pernille
    Johansen, Odd Erik
    Zwiener, Isabella
    George, Jyothis T.
    Butler, Javed
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1859 - 1859
12345